Key result
The expansion of transcatheter aortic valve implantation (TAVI) to intermediate- or low-risk patients with severe aortic stenosis remains a subject of debate with many unknowns.
Why the study?
Is there a justification for expanding the indication of TAVI to intermediate- or low-risk patients with symptomatic severe aortic valve stenosis?
Is there a justification for expanding the indication of TAVI to intermediate- or low-risk patients with symptomatic severe aortic valve stenosis?
This editorial discusses the potential justification and unknowns regarding the expansion of TAVI indications to intermediate- and low-risk patients from a surgeon's perspective.
The introduction of transcatheter aortic valve implantation (TAVI) has revolutionised the treatment of patients with symptomatic severe aortic valve stenosis (AS). In extreme and high-risk patients, randomised studies have shown the benefit of this new therapy. However, there are still a lot of unknowns, and the question has arisen whether it is justified to expand the indication of TAVI to other patient groups, especially intermediate-or even low-risk patients.
No takes yet. Share an insight, caveat, or question.
Kappetein et al. (2014) conducted an editorial in symptomatic severe aortic valve stenosis (AS). transcatheter aortic valve implantation (TAVI) was evaluated. The expansion of transcatheter aortic valve implantation (TAVI) to intermediate- or low-risk patients with severe aortic stenosis remains a subject of debate with many unknowns.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: